#41 - Investor as a ‘Partner in Progress’ Beyond Capital, and the Road Ahead for Bugworks

Continuing from Part 1, we dive deeper into the long-standing relationship between Bugworks Research and UTEC, and explore what the future holds for the company and for science-driven entrepreneurship.This half focuses on how founders and investors can work together as true partners — especially through uncertainty, global crises, and long development cycles.In this episode, we discuss:- How UTEC and Bugworks first met, and what sparked the partnership- Navigating the pandemic, fundraising challenges, and global supply-chain disruptions- Why Anand refers to UTEC as an “Investor Partner,” not just a VC- How entrepreneurs can build meaningful, long-term relationships with investors- What success looks like for Bugworks over the next 5–10 years- Where AI can make the biggest impact in drug discovery- A message to young scientists and researchers across Asia considering entrepreneurship★Bugworks Researchhttps://bugworksresearch.com/★Dr. Anand AnandkumarDr. Anandkumar is a serial entrepreneur in biotechnology and semiconductor domains. Before Bugworks, he was co-founder and MD at Cellworks Research India Pvt. Ltd, a company that pioneered the use of systems biology and semiconductor technologies in creating directed therapies in cancer care. Before Cellworks, Anand spent 18 years in the semiconductor industry, donning technical and global-executive roles in USA/EU/Japan/China and India. Anand is also a co-founder in Impres Healthcare, an incubator promoting innovation in biomedical sciences. He serves as a member of GARDP India advisory board, former member of the Board of AMR Industry Alliance, ex-Vice President of the India Biotech Association and a founding member of the India Electronics and Semiconductor Association (IESA).★UTECへの投資・起業のご相談はこちらhttps://share.hsforms.com/1_WfJXAagSWmKnsxVxSalXQc3fla★UTEC投資先参画や研究機関発スタートアップインキュベーション支援に関心のある方向けのコミュニティSOC（Startup Opportunity Club）についてhttps://www.ut-ec.co.jp/recruit/soc/